Working… Menu

Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01519687
Recruitment Status : Unknown
Verified January 2012 by Pharmos.
Recruitment status was:  Recruiting
First Posted : January 27, 2012
Last Update Posted : January 27, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine whether levotofisopam is safe and effective in the treatment of hyperuricemia and gout.

Condition or disease Intervention/treatment Phase
Hyperuricemia Gout Drug: levotofisopam Phase 2

Detailed Description:
The primary objectives of this study are (1) to evaluate the safety and tolerability of levotofisopam in patients with hyperuricemia and gout, and (2) to evaluate the effect of treatment with levotofisopam on serum urate levels in these patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Inpatient Study of Levotofisopam 50 mg TID Administered for 7 Days to Men and Postmenopausal Women With Hyperuricemia and Gout
Study Start Date : January 2012
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Gout
MedlinePlus related topics: Gout

Arm Intervention/treatment
Experimental: Levotofisopam
All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.
Drug: levotofisopam
50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
Other Name: S-tofisopam

Primary Outcome Measures :
  1. Percentage reduction in serum urate [ Time Frame: Days 1-7 ]
    The primary efficacy variable is the percentage reduction in serum urate from baseline to Day 7 on treatment with levotofisopam.

Secondary Outcome Measures :
  1. Absolute reduction in serum urate from baseline [ Time Frame: Days 1-7 ]
    Secondary efficacy variables include absolute reduction in serum urate from baseline to Day 7 on treatment with levotofisopam, proportion of subjects with serum urate < 6 mg/dL on Day 7, change in fractional excretion of urate from baseline to Day 6, and change in 24-hour urinary uric acid from baseline to Day 6.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provide voluntary, signed informed consent.
  • Male or postmenopausal or surgically sterile females, 18 to 65 years of age, inclusive. Female participants must have been amenorrheic for a minimum of 12 months and must have a negative pregnancy test result within 3 days before administration of levotofisopam. Surgically sterile females are defined as those who have had a hysterectomy, bilateral ovariectomy, or bilateral tubal ligation. Male subjects must agree to practice a medically acceptable form of contraception for the duration of the study and for 30 days after receiving the last dose of levotofisopam.
  • Physician diagnosis of gout with at least one gout flare in the last 6 months, at least one chronically swollen joint due to gout, or presence of a tophus.
  • Serum urate level ≥ 8.0 mg/dL and ≤ 12.0 mg/dL after having stopped all urate-lowering therapy for at least 10 days. Serum urate level must also be > 7.7 mg/dL and ≤ 12.0 mg/dL on Day -3 and on Day -2.
  • Willing and able to discontinue urate-lowering therapy starting at the screening visit (14-21 days before receiving study drug) through to the follow-up visit (up to 10 days after discharge from the study unit), for a total time off urate-lowering therapy of up to approximately 5 weeks.
  • In the opinion of the investigator, able to participate in all scheduled evaluations, likely to complete all required tests, and likely to be compliant.
  • Medications permitted for the treatment of non-excluded medical conditions (other than gout) must be at stable doses for at least 14 days prior to baseline.
  • Permitted concurrent general medical conditions must be stable and well controlled.
  • Written and oral fluency in the English language.

Exclusion Criteria:

  • Previous treatment with racemic tofisopam (RS-tofisopam), levotofisopam (S-tofisopam), or dextofisopam (R-tofisopam).
  • Known or suspected hypersensitivity to any benzodiazepine.
  • History of two or more clinically significant drug allergies.
  • Clinically significant infection within 30 days prior to screening or between screen and admission.
  • History or presence of clinically significant medical disease that might compromise the study or be detrimental to the patient, such as hepatitis (patient excluded if hepatitis A was present within 2 years before screening or if there is any history of hepatitis B or C), human immunodeficiency virus (HIV) infection, uncontrolled diabetes mellitus, cirrhosis, active biliary disease (bile ducts or gallbladder), or moderate or severe chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73 m2).
  • Presence of a gout flare during screening or the procedure window.
  • History or presence of nephrolithiasis.
  • History or presence of malignancy other than localized basal cell cancer, squamous cell skin cancer, or cancer in situ that has been resected within 5 years.
  • Clinically significant head trauma with loss of consciousness within 10 years prior to screen.
  • Myocardial infarction, congestive heart failure, or known coronary artery disease within 5 years prior to screen.
  • Any history of cerebrovascular accident.
  • History of seizure disorder other than a single childhood febrile seizure.
  • Alcohol or psychoactive substance abuse or dependence, as defined by DSM-IV, within 1 year prior to screen, or alcohol use exceeding 21 units per week (on average) in the 3 months preceding screen.
  • Used any tobacco- or nicotine-containing product more days than not within 30 days prior to screening or between screen and admission.
  • Regular consumption (e.g., more days than not) of excessive quantities of caffeine-containing beverages (e.g., more than eight cups of coffee or equivalent per day) within 30 days prior to screening or between screen and admission.
  • History of suicide attempt, any suicidal behavior within 6 months prior to screening or between screen and baseline, or, in the opinion of the investigator, clinically significant risk of suicide or violent behavior.
  • History or presence of a clinically significant psychiatric disorder or symptom (e.g., delusions, hallucinations) that is likely to compromise the study (e.g., confound study results) or be detrimental to the patient.
  • History of difficulty donating blood, or history or presence of clinically significant bleeding or hemorrhagic tendencies.
  • Donation of blood or plasma within 90 days prior to screening or between screening and admission.
  • Uncontrolled hypertension (systolic blood pressure > 160 mmHg and/or diastolic > 95 mmHg) or heart rate either < 50 BPM or > 100 BPM at any evaluation prior to the first dose of test drug.
  • Pregnancy, lactation, a positive pregnancy test result during the screening or admission evaluation.
  • A clinically significant abnormality on the screening physical examination, 12-lead electrocardiogram (ECG), or laboratory evaluations.
  • A corrected QT (QTcF) value > 450 msec (males) or > 470 msec (females) at screening, admission (Day -3), or baseline (Day -1).
  • Aspartate aminotransferase or alanine aminotransferase levels > 2 times upper limit of normal (ULN), alkaline phosphatase > 1.5 times ULN, creatinine outside the limits of normal, triglycerides > 500 mg/dL, or thyroid-stimulating hormone (TSH) levels greater than 6.0 µIU/L at screening, admission (Day -3), or Day -2.
  • A finding of opiates, amphetamines, cocaine, cannabis, or phencyclidine on the urine drug screen (UDS). Any other positive UDS result must be discussed by the investigator and medical monitor prior to potentially allowing participation of the subject in the study.
  • A positive HIV, hepatitis B, or hepatitis C test.
  • Inability to take or tolerate colchicine for gout flare prophylaxis (0.6 mg QD or BID).
  • Required use of any of the following from the screening visit through the follow-up visit: aspirin or other nonsteroidal antiinflammatory drugs (other than paracetamol, as noted below), diuretics, medications with known urate-lowering effects (including, but not limited to, fenofibrate, losartan, or vitamin C > 500 mg/day), or urate-lowering therapy other than levotofisopam.
  • Dietary requirements inconsistent with the study unit's standardized diet.
  • Body mass index ≥ 35.
  • Use of any investigational treatment within 30 days prior to screening or between screen and admission.
  • Use of any psychopharmacologic drug or substance within 7 days of screening or between screen and admission.
  • Use of potent CYP3A4 inhibitors or potent CYP3A4 inducers within 7 days prior to screening or between screen and admission.
  • An estimated 24-hour uric acid excretion > 1,000 mg/day.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01519687

Layout table for location contacts
Contact: John S. Sundy, MD, PhD (919) 684-2347
Contact: Lou Cappoli, MBA (919) 684-4888

Layout table for location information
United States, North Carolina
Duke Clinical Research Unit (DCRU) Recruiting
Durham, North Carolina, United States, 27720
Contact: John S. Sundy, MD, PhD    919-684-2347   
Contact: Lou Cappoli    (919) 684-4888   
Principal Investigator: John S. Sundy, MD, PhD         
Sub-Investigator: Robert Noveck, MD, PhD         
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: John S. Sundy, MD, PhD Duke Clinical Research Unit
Layout table for additonal information
Responsible Party: Pharmos Identifier: NCT01519687    
Other Study ID Numbers: PRS-TOFS-G201
First Posted: January 27, 2012    Key Record Dates
Last Update Posted: January 27, 2012
Last Verified: January 2012
Keywords provided by Pharmos:
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Pathologic Processes
Antidepressive Agents
Psychotropic Drugs